YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

12 Customer Reviews

  • MM cell lines UM9 (left panel) or U266 (right panel) were cultured in presence or absence of accessory cells prior to incubation with CTLs alone, YM155 alone or the combination. Survival of UM9 and U266 MM cells was assessed by CS-BLI. Results show % lysis of MM cells after 24 hour incubation and are depicted for three doses.

    Clin Cancer Res 2013 19, 5591-601. YM155 (Sepantronium Bromide) purchased from Selleck.

    Dose response of ALL cell lines to YM155. Asynchronous populations of cells were treated with increasing doses of YM155 for 72 h. Then, viability was measured by MTS and normalized to no drug control. S.e.m. bars are inserted. Dotted line represents 50% viability.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Treatment of SUPB15 cells with imatinib or YM155. Top panel shows cells treated with siRNA in the presence of 500 nM imatinib. Cells were treated with siRNA, and then subsequently incubated in 500 nM imatinib for 96 h. Bottom panel shows the partial rescue of SUPB15 cells treated with 100 nM YM155 for 96 h. S.e.m. bars are inserted into each graph.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

    Inhibition of survivin expression restricts VZV repl ication and sprea d in vitro . ( A ) HEL F were infected w ith VZV-GFP in the presence of YM155 or DMSO, and infectious virus yields were determined at 48 hpi by titration on melanoma cells. ( B) VZV-GFP-infected HELF were treated with DMSO or YM155; plaques were detected by staining with anti-VZV IgG at 48 hpi. Plaque sizes were determined using ImageJ; the graph shows the mean size ?S EM o f 30 plaques . (C )Expression of VZV proteins was assessed in VZV-infected HELF lysat e s (24 hp i) treated with YM155 or DMSO.

    Proc Natl Acad Sci U S A 2012 109, 600-5. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Survivin inhibitor increased apoptosis in burn serum-stimulated cardiomyocytes. a YM155 increased apoptosis in burn serumstimulated cardiomyocytes in a concentration-dependent manner. Neonatal rat cardiomyocytes were treated with YM155 (3-300 nM at the indicated) for 2 h prior to stimulation burn serum for 12 h. The extent of DNA fragmentation was quantified using the Cell Death Detection ELISA. versus 0 nM YM155 plus stimulation with burn serum. b YM155 (100 nM) pretreatment increased the apoptosis production at 2 or 12 h after burn serum stimulation. c Representative blots of survivin and cleaved caspase-3 in YM155 (100 nM) pretreated cardiomyocytes at 2 and 12 h after burn serum stimulation. d Bar graphs show the relative proteins.

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

    Induction of cardiomyocytes apoptosis by survivin inhibitor in vivo. After YM155 was administered (5 mg/kg/day) for 5 days, the rats were exposed to a 40% TBSA burn (burn injury) or 25C water (sham) and killed 6 h after burn injury. The frozen sections of the ventricular tissues or whole cell lysates were prepared. Apoptotic staining was performed using the TUNEL method and immunostained using a-sarcomeric actin. The survivin and cleaved caspase-3 levels were measured by Western blot analysis. a Representative blots of survivin and cleaved caspase-3. b The statistical analysis of the relative proteins .c Figures are representative of two independent TUNEL experiments. Green fluorescence represents apoptotic cells, whereas red stain indicates staining for a-sarcomeric actin specific for cardiac myocytes. d Bar graph summarizes the counted apoptotic cells.

     

     

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

  • YM-155 sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 and B. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for up to 6 h. Then apoptotic cells were assessed as in Figure 2A and2B (representative apoptotic cells were marked with white arrows). C. LH86 and D. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for 6 h. Cells with apoptotic nuclei were counted to determine cell death ratio (*p<0.05, **p<0.05). E. LH86 cells and F. Huh7 cells were treated as indicated and cell lysates were prepared and subjected to Western blotting.Apoptosis was evaluated through caspase 3 activation. b-actin was used as an equal protein loading control. G. LH86 cells grown in six-well plate were untreated (control) or treated with different conditions as indicated for 48 h. After rinsed with fresh culture medium for 3 times, cells were cultured for another two weeks. Cell colony formation assays were performed with crystal violet staining. H. colony number were counted to show combination treatment with ABT-263 and YM-155 resulted in reduction of clonogenesis (#p<0.05).

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

    Survivin down-regulation sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 cells were treated as indicated and cell lysates were prepared for Western blotting. Pro-apoptotic proteins: Bax, Bad, and Bak and anti-apoptotic proteins Bcl-xL and Mcl-1 were assessed with specific antibodies respectively. b-actin was detected and served as an equal protein loading control. B. LH86 cells were untreated or treated with ABT-263 (1 μM), YM-155 (1 μM) or combination of ABT-263 (1 μM) and YM155 (1 μM) for up to 6 h as indicated. Then cells were harvested and cell lysates were prepared for Western blotting. Anti-survivin and anti-Bcl-xL polyclonal antibodies were used to assess protein levels for survivin and Bcl-xL respectively. b-actin was used as an equal protein loading control. The band intensities of survivin, Bcl-xL, and b-actin was qualified with Image J software. C. LH86 cells were transiently transfected with synthesized random siRNA (control) or survivin specific siRNA duplexes, and 48 h posttransfection, cells were subjected to Western blotting analysis with anti-survivin polyclonal antibody. β-actin was used as an equal protein loading control. D. LH86 cells were transfected with synthesized random control siRNA or survivin specific siRNA, and 48 h post-transfection, cells were untreated or treated with ABT-263 (1 μM) for 24 h and then subjected to Hoechst staining to show apoptotic cells with condensed nuclei (representative apoptotic cells were marked with white arrows). E. LH86 cells were treated as in Figure 4D and apoptosis was measured as in Figure 2A. Statistical analysis was performed for apoptosis ratio by counting the number of cells with apoptotic nuclei (*p<0.05). F. LH86 cells treated as in Figure 4D were harvested and cell lysates were prepared and subjected to Western blotting. Apoptosis was determined through caspase 3 activation. β-actin was used as an equal protein loading control.

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Effects of YM155 on cell viability (A) and cell cycle (B), and on experiment of survivin mRNA (C) and protein (D) in the MiaPaCa-2 human pancreatic cancer cell line.

    Anticancer Res 2012 32, 1681-8. YM155 (Sepantronium Bromide) purchased from Selleck.

     

    IPF fibroblasts from 8 different patients were cultured to 60% confluence in DMEM supplemented with 10% fetal bovine serum and growth-arrested for 24 hours in serum-free DMEM prior to treatment for 16 hours with/without the Fas-activating antibody CH11 (FasL; 250 ng/ml) in the presence/absence of the survivin inhibitors CAY10625 (5 µM) or YM155 (10.0 µM), or with the survivin inhibitors alone. (a) Apoptosis was assessed using ELISA-based detection of histone associated DNA fragments. To allow relative comparisons of apoptosis across experiments, the data for each cell line is expressed as the percentage of the assay positive control that was included on each ELISA plate. The scatter plot shows the distribution of responses in individual cell lines along with the mean ± standard error for each treatment group. p = 0.038 overall (ANOVA). p = 0.027 for FasL compared to FasL/CAY10625, and p = 0.046 for FasL compared to FasL/YM155; (b) The correlation of apoptosis between IPF fibroblasts treated with FasL/CAY10625 and FasL/YM155. Each point represents a different IPF cell line. The Spearman correlation (r) = 0.95.
     

    Adv Biosci Biotechnol 2012 3, 657-664. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Total RNA from livers of these mice were isolated from tissues using TRIZOL (Invitrogen). cDNA synthesis was performed with the M-MLV RTase cDNA Synthesis Kit (Promega). qRT-PCR reactions were performed using SYBR Green (Takara) on ABI 7500 Fast system. Expression levels of Survivin gene were measured by qRT-PCR in livers injected with 0.9% Nacl (91#,92#) or YM155 48 hours after DEN treatment.

    Lihua Min of Chinese Academy of Sciences. YM155 (Sepantronium Bromide) purchased from Selleck.

    Western blot analysis of Survivin. U-251 and PC-3 cell line was treated with 0-100nM YM-155.

     

     

    Dr. Chunrong Yu of RoswelI Park Cancer Institute. YM155 (Sepantronium Bromide) purchased from Selleck.

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NEG4e5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XhclczKGh? MYXEUXNQ MnzDTWM2OD1yLkCwPUDDuSByLkCwNFkh|ryP MU[yOVY2QTd|MR?=
M-07e MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnKNWZOPzJiaB?= NEnzN3FFVVOR NFi4TGtKSzVyPUCuNFQxKMLzIECuNFE{KM7:TR?= MYiyOVY2QTd|MR?=
THP-1 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fkfFczKGh? MonDSG1UVw>? MnzITWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? MXGyOVY2QTd|MR?=
CMK Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX23NkBp MVfEUXNQ MYHJR|UxRTBwMEWzJOKyKDBwMEC5JO69VQ>? MUWyOVY2QTd|MR?=
MV4-11 NUD6OYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK2W3VKPzJiaB?= Mlr2SG1UVw>? MofYTWM2OD1yLkC1OUDDuSByLkCyPEDPxE1? Mn\ZNlU3PTl5M{G=
AML-193 NFjqNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z3TlczKGh? M1nqPWROW09? Mn\kTWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? M1r1PFI2PjV7N{Ox
HL-60 M3LtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvoWVc4OiCq M4fad2ROW09? MVnJR|UxRTBwMECxJOKyKDBwMECwNkDPxE1? M3zWZlI2PjV7N{Ox
ML-2 M3mzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv1co04OiCq MY\EUXNQ MXrJR|UxRTBwMEC5JOKyKDBwMECyJO69VQ>? NGi0TFYzPTZ3OUezNS=>
OCI/AML3 NXfrc3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp NIflTmtFVVOR NULk[Y1{UUN3ME2wMlAyOSEEsTCwMlAxOiEQvF2= MlfiNlU3PTl5M{G=
HEL NUXoSlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ZdFczKGh? MmLJSG1UVw>? NF\y[pVKSzVyPUCuOVU6KMLzIECuNFM5KM7:TR?= NXn2ZY5GOjV4NUm3N|E>
ME-1 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjNO|IhcA>? M1vpbWROW09? MlrvTWM2OD1yLk[4OEDDuSByLkG3PUDPxE1? MVyyOVY2QTd|MR?=
THP-1 MUPBdI9xfG:|aYOgRZN{[Xl? MmD6NeKh|ryP MUS3NkBp NIj4WZlFVVOR NW[wXIZOcW6mdXPld{BieG:ydH;zbZM> Mn\DNlU3PTl5M{G=
M-07e M2OzOWZ2dmO2aX;uJGF{e2G7 NWLBcnJ7OOLCk{JCpO69VQ>? NWTZ[Xd3PzJiaB?= NGLic2FFVVOR NHf3VHZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu M1;4fFI2PjV7N{Ox
THP-1 MXzGeY5kfGmxbjDBd5NigQ>? MWew5qCUOcLizszN MXm3NkBp M1TDb2ROW09? NV\VbZdIcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MVSyOVY2QTd|MR?=
CMK MXrGeY5kfGmxbjDBd5NigQ>? MnTINQKBmzIEoN88US=> MnjDO|IhcA>? MVnEUXNQ NGHuSnZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NYXDPHlwOjV4NUm3N|E>
AML-193 NEftSZVHfW6ldHnvckBCe3OjeR?= NET2b5Qx6oDVMdMg{txO NW[4[lVXPzJiaB?= M323cmROW09? NEnJUo9qdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu M{fXUlI2PjV7N{Ox
Kasumi-1 M{HqZWZ2dmO2aX;uJGF{e2G7 NF;rc2kx6oDVMdMg{txO MUS3NkBp MXrEUXNQ M3fpfYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= MUSyOVY2QTd|MR?=
MV4-11 NX3vdYpXTnWwY4Tpc44hSXO|YYm= MWWw5qCUOcLizszN NGHhRYM4OiCq MVvEUXNQ NHmzbINqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MnzNNlU3PTl5M{G=
MUG-Chor  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjSS|UxNTVizszN NYPIdZFWOjRxNEigbC=> NVHZVWFVUUN3ME23MlA26oDLbl2g[o9zKDR6aB?= MWCyOVY1ODF6NR?=
U-CH1  NW\CTI5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrkNE02KM7:TR?= NH:1PIgzPC92ODDo NVPlWIx[UUN3ME25MlA{6oDLbl2g[o9zKDR6aB?= NELkeHozPTZ2MEG4OS=>
KATOIII NHTtOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHPV4oyOC9{MDDuUS=> MnT5OFghcA>? NGLHSXVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3rteVI2PjN3MEW1
AGS  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[zZ5UyOC9{MDDuUS=> MWC0PEBp MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYX3V3lJOjV4M{WwOVU>
SACC-83 NXLONWVUTnWwY4Tpc44hSXO|YYm= M1jWXVUhdk1? M{C5dlQ5KGh? MWfk[YNz\WG|ZYOgcpVkdGWjcjDlfJBz\XO|aX;uJI9nKEiLRj2x{tE> MVSyOVQ5PTZ|NR?=
INA-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfLNmgxNTVyMDDuUS=> MX:0PEBp M1;NSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHe4[m0zPTJ7Nkm3PC=>
U-266 M3LVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPyS4VYOC13MECgcm0> NYftdGpHPDhiaB?= MlzmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUKyOVI6Pjl5OB?=
MOLP-8 NUTwWW9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\iNE02ODBibl2= NX\oS5BqPDhiaB?= MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHzC[FgzPTJ7Nkm3PC=>
HG-1 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vsblAuPTByIH7N NInCXYQ1QCCq NHG4bYZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUKyOVI6Pjl5OB?=
NCI-H929 M1jPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv2NE02ODBibl2= NWi3WWd2PDhiaB?= NHnWPI9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2\FflI2Ojl4OUe4
OPM-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHVNE02ODBibl2= NWnRUXd3PDhiaB?= MmmxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoHHNlUzQTZ7N{i=
L-363 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[5OWZuOC13MECgcm0> MljyOFghcA>? NV2zXYxYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWi3fGtuOjV{OU[5O|g>
MOLP-2 NHzKUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSwMVUxOCCwTR?= NXHp[296PDhiaB?= NY[ydoRicW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXGyOVI6Pjl5OB?=
KMS-12-BM MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGwMVUxOCCwTR?= NHO1flQ1QCCq NHLUOnFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnnDNlUzQTZ7N{i=
SK-MM-2 M3KwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXqN2QxNTVyMDDuUS=> M{PZTVQ5KGh? NIT4VXBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mo[3NlUzQTZ7N{i=
U-266 NVe5UnJrSXCxcITvd4l{KEG|c3H5 MYqwMVUxKG6P M3;oSVI1KGh? NXzCfW5ZcW6mdXPld{BieG:ydH;zbZM> NWTxO41HOjV{OU[5O|g>
INA-6  M3\EVWFxd3C2b4Ppd{BCe3OjeR?= M2nEbFAuPTBibl2= Moi3NlQhcA>? MWfpcoR2[2W|IHHwc5B1d3Orcx?= NVzCUZY{OjV{OU[5O|g>
MCF7 NVTLdlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYm3NkBp NHjyS5RKSzVyPUGzJOKyKDZibl2= MVGyOVIzODJ{NR?=
MCF7-TamR6 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXrO|IhcA>? M{HRNWlEPTB;ODFCtUA3KG6P NIrqd3EzPTJ{MEKyOS=>
MCF7-TamR7 NH61SHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:3NkBp M2\KTGlEPTB;ODFCtUA{KG6P M4HrUlI2OjJyMkK1
MCF7-TamR8 NH2xTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[3NkBp MnvYTWM2OD1zNTFCtUA3KG6P NHHiTJozPTJ{MEKyOS=>
MCF7-TamC3 NV61dox7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPkOpk4OiCq MW\JR|UxRTZiwsGgN{BvVQ>? MmPkNlUzOjB{MkW=
MCF7-TamC6 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD1O|IhcA>? NF;1XYdKSzVyPU[gxtEhOC5zIH7N MUKyOVIzODJ{NR?=
MDA-MB-231 NF63OHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjHO|IhcA>? MUDJR|UxRTViwsGgNUBvVQ>? MYmyOVIzODJ{NR?=
SK-BR-3 NFjkSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m4V|czKGh? M3viUmlEPTB;NzFCtUAxNjNibl2= M2\tcVI2OjJyMkK1
Eca109 MYHGeY5kfGmxbjDBd5NigQ>? NUjlZmQ4OS13MDDuUS=> NVLtNGt{PDhiaB?= MUXEUXNQ NEDTTWJ{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlrpNlUyOzl|OUW=
TE13 MknESpVv[3Srb36gRZN{[Xl? MnLtNU02OCCwTR?= MnvNOFghcA>? MUPEUXNQ Mknpd5VxeHKnc4Pld{B{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NXTmeo1OOjVzM{mzPVU>
Eca109 NETJNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOwMVExOCCwTR?= M3fDeVI1NzR6IHi= MnG4SG1UVw>? NU\Tbmxm\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGjTUmQzPTF|OUO5OS=>
TE13 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj3N|c{OC1zMECgcm0> M4HheVI1NzR6IHi= NVf1UYtrTE2VTx?= MWPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnrsNlUyOzl|OUW=
MT-3 Mm\JT4lv[XOnIFHzd4F6 MonXO|IhcA>? NX;hXVRYTE2VTx?= NYCzb5BFUUN3ME2yMlg3KMLzIECuOVQhdk1iZn;yJGRTPCCneIDy[ZN{cW:w MYeyOFg3PjV6NR?=
MDA-MB-468 NIm5WZFMcW6jc3WgRZN{[Xl? MWG3NkBp MWHEUXNQ M1;PWWlEPTB;MD6xNUDDuSByLkCxJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? Mn\2NlQ5PjZ3OEW=
SUM-159 MUHLbY5ie2ViQYPzZZk> MXu3NkBp NG\UNW9FVVOR NHfJZY9KSzVyPUGuO|IhyrFiMD6zN{BvVSCob4KgSHI1KGW6cILld5Nqd25? MV:yOFg3PjV6NR?=
MT-3 NFvBNIdMcW6jc3WgRZN{[Xl? NUjiO2QyPzJiaB?= Mli1SG1UVw>? NUD2T4tZUUN3ME21OE4yOSEEsTC0MlMzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= MV6yOFg3PjV6NR?=
MDA-MB-468 M4rTbWtqdmG|ZTDBd5NigQ>? NFHkfnE4OiCq MV\EUXNQ NFfpO45KSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? NFvKO|QzPDh4NkW4OS=>
SUM-159 NIS2SIpMcW6jc3WgRZN{[Xl? M{\0OFczKGh? MVXEUXNQ MYPJR|UxRTZ7LkSgxtEhPC5{MzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> NFfufFIzPDh4NkW4OS=>
MT-3 + NAC MVXLbY5ie2ViQYPzZZk> NILyRXk4OiCq M3e0bWROW09? MYrJR|UxRTV4LkKgxtEhOi5yNzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> MX2yOFg3PjV6NR?=
MT-3 + SB203580 MnvFT4lv[XOnIFHzd4F6 NFftSZk4OiCq NHf0PGVFVVOR NVG1Um9ZUUN3ME2zPE41OSEEsTC1MlAzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= Ml;oNlQ5PjZ3OEW=
DB MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DGclExKG6P MW[yOEBp M1XrXWROW09? NYf5TZFJcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v M2GxW|I1PDh4NUm1
SU-DHL-8 NWHOeIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q4N|ExKG6P MVyyOEBp M3;3UGROW09? NXf1U|NVcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NXq5NJJDOjR2OE[1PVU>
WSU-DLCL2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPnNVAhdk1? M4jhbFI1KGh? NX7y[IRGTE2VTx?= NIC1doRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MVWyOFQ5PjV7NR?=
ACC-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz0NE0yODBibl2= Ml6zNlQhcA>? MlTDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{jXZ|I1OzdyOUm1
ACC-2 MV7BdI9xfG:|aYOgRZN{[Xl? MXWwMVIxKG6P MlfKNlQhcA>? MX;pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NH\wTZEzPDN5MEm5OS=>
ACC-2 M17LfWZ2dmO2aX;uJGF{e2G7 NWHoR2w1OC1{MDDuUS=> NWjP[VRnOjRiaB?= NHH0PGdqdmO{ZXHz[ZMhfGinIHPvcpZmenOrb36gc4YhVEN|STD0c{BNSzOLSR?= M4rFc|I1OzdyOUm1
BFTC905 NITQOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf0TpgxNTFyMECgcm0> MnjUOFghcMLi MWDEUXNQ MlzVTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2HKW|I1Ojl5NkS0
T24 M2fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z2R|AuOTByMDDuUS=> NHTmN2w1QCCqwrC= M4TUOGROW09? NWLObHFsUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4nKTlI1Ojl5NkS0
TSGH8301  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nhSlAuOTByMDDuUS=> NX:3N3d5PDhiaNMg Mm\pSG1UVw>? MlzwTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVvzVowzOjR{OUe2OFQ>
BFTC909 NIj0Ro5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMVExODBibl2= NX[4PZkzPDhiaNMg MUHEUXNQ M2KxfGlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH62d2EzPDJ7N{[0OC=>
BFTC905 NIG2Z2JCeG:ydH;zbZMhSXO|YYm= NE\hdGUzOCCwTR?= M2P2[|Q5KGh? MUXEUXNQ NHHafW9qdmS3Y3XzJIFxd3C2b4Ppdy=> MonRNlQzQTd4NES=
BFTC905 NX3lNFZRTnWwY4Tpc44hSXO|YYm= MVuyNEBvVQ>? NIrtUVk1QCCq NIfrNZNFVVOR NFrZUYJl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|Qj3JTS=> Mle4NlQzQTd4NES=
A2780p NUj1TYJGTnWwY4Tpc44hSXO|YYm= NWjycZVbOC1zMECgcm0> MonmNlQhcA>? NVXUbIxbTE2VTx?= NXXVXVdncW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg MkfONlQzPjJ6N{W=
A2780cis MWHGeY5kfGmxbjDBd5NigQ>? M3LkZVAuOTByIH7N Mn7iNlQhcA>? MmnxSG1UVw>? MW\pcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? M4XrdVI1OjZ{OEe1
A2780p NV;6fIdSSXCxcITvd4l{KEG|c3H5 NVPJfodWPS1zMECgcm0> NGTFfIczPC92ODDo NVjNdXNUTE2VTx?= NEjqT2dqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NILNTYYzPDJ4Mki3OS=>
A2780cis M1K0UGFxd3C2b4Ppd{BCe3OjeR?= MkTyOU0yODBibl2= MYiyOE81QCCq M33ETGROW09? NF63bWxqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NFrpcIkzPDJ4Mki3OS=>
SH-SY5Y MWXBdI9xfG:|aYOgRZN{[Xl? MUSxM|ExNzFyMDFCuW0> NXPJR3ZCPzJiaB?= NWjmO3ZqTE2VTx?= NX7x[ppmcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYmxSJNGOjR{NUS1OlA>
HL-60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3OO|LDqGh? MlHHSG1UVw>? MWHJR|UxRTBwMzDuUS=> MUKyN|YyQDh4Mh?=
U937  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjqO|LDqGh? NW[0eFJ5TE2VTx?= MmnKTWM2OD1yLkigcm0> NE\TemszOzZzOEi2Ni=>
HL-60  NGW0dFZHfW6ldHnvckBCe3OjeR?= M3;pVlHDqM7:TR?= MmfSOk8yOi9{NDDo MULEUXNQ M2noW4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu NHjvT2szOzZzOEi2Ni=>
U937  NVjhOIpFTnWwY4Tpc44hSXO|YYm= M2SzXlHDqM7:TR?= M4fRSFYwOTJxMkSgbC=> MVrEUXNQ NV:w[IRWcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> NGq1UIkzOzZzOEi2Ni=>
HL-60 NH\PNHpCeG:ydH;zbZMhSXO|YYm= NVzPV|U5OC5zL{Gg{txO NUjkTGpQQCCq Mk\VSG1UVw>? NHLRdVVqdmS3Y3XzJIFxd3C2b4Ppdy=> MYiyN|YyQDh4Mh?=
Sk-NEP-1  NW\hXYJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln0NU0yODByMDDuUS=> M2jyelI1KGh? NFHuPItFVVOR MULJR|UxRTFyMDDuUS=> NVTaRW5pOjN{Nke2PVk>
SK-NEP-1  M1LOWGFxd3C2b4Ppd{BCe3OjeR?= NGO3[og2OC9zMECgcm0> MUKxNk8zPCCq MkDySG1UVw>? NHnXT|NqdmS3Y3XzJIFxd3C2b4Ppdy=> NF7Od|kzOzJ4N{[5PS=>
TC-32 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfOXHAxNjFvMUCwNEBvVQ>? NWLoPYt1TUN3ME2zMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnvKNlI6PjF5NkO=
TC-71 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzqcHExNjFvMUCwNEBvVQ>? NFHMOWFGSzVyPUWuO{BvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXGyNlk3OTd4Mx?=
SK-ES-1 M{LoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrESFkxNjFvMUCwNEBvVQ>? MkLnSWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3P1bFIzQTZzN{[z
RD-ES M2CzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nJU|AvOS1zMECwJI5O MnHPSWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXXqeJVXOjJ7NkG3OlM>
HEK293 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrDSnJ1OC5zLUGwNFAhdk1? NYXIepZqTUN3ME2yN{4xKG6PLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFO4VVYzOjl4MUe2Ny=>
M059J NXu5WZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\6T2cxNTVyIH7N NX2zTYpJPDhiaB?= NHjFOFRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4\CTlIzPzdyMUGw
M059K NGnMNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTidIRzOC13MDDuUS=> MWG0PEBp NHPwVWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NELlV44zOjd5MEGxNC=>
M059J M2rnOWFxd3C2b4Ppd{BCe3OjeR?= MmTnN|Ahdk1? NYDjZmF2OjRiaB?= Mke0bY5lfWOnczDhdI9xfG:|aYO= M4HieFIzPzdyMUGw
M059K Mmn0RZBweHSxc3nzJGF{e2G7 NGfwT|I{OCCwTR?= MV2yOEBp NILldlJqdmS3Y3XzJIFxd3C2b4Ppdy=> MYSyNlc4ODFzMB?=
PANC-1 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXDUW4xNjBzLUGwNFAhdk1? NH;o[lc1QCCq NH\0VW9KSzVyPUOuOlkhdk1? NEDhc3QzOjd{M{i3NS=>
MIAPaCa-2 NIrqT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMlAyNTFyMECgcm0> NIfiUXU1QCCq Mn7TTWM2OD1{OT6zOkBvVQ>? MnnTNlI4OjN6N{G=
BxPC-3 NX;rS|U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMlAyNTFyMECgcm0> MkfLOFghcA>? NGfnO5dKSzVyPUOwMlI3KG6P NWOyPIpHOjJ5MkO4O|E>
PANC-1 M2nsOWZ2dmO2aX;uJGF{e2G7 MlPuNE0yODByIH7N Mli5NlQhcA>? M3XOWolv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> MoHVNlI4OjN6N{G=
MIAPaCa-2 MUjGeY5kfGmxbjDBd5NigQ>? MnTWNE0yODByIH7N MYqyOEBp NEL1SFNqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MomyNlI4OjN6N{G=
BxPC-3 M{nucWZ2dmO2aX;uJGF{e2G7 NXG5elNvOC1zMECwJI5O MkG5NlQhcA>? NUDNPYtCcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v M2DwXVIzPzJ|OEex
RPMI-7951 NHnLXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvtfZRIUTVyPUOuNkBvVQ>? M3vSOlIyPzN5NUCy
SK-MEL-5 NFX4emlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Vb2J5T0l3ME20MlIhdk1? MUCyNVc{PzVyMh?=
A375 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SxcWdKPTB;Nj6zJI5O NWHQbVViOjF5M{e1NFI>
SK-MEL-28 NIO1ZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L6NWdKPTB;Nz62JI5O NUjtfWtWOjF5M{e1NFI>
SK-MEL-2 NHzrW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELFXJJIUTVyPUGxJI5O Mly1NlE4Ozd3MEK=
DB M37ZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\uOFjDqGh? MknRS2k2OD1|LkWgcm0> NIGxUm4zOTJ|N{WwPC=>
Pfeiffer MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi0POKhcA>? NInqVXpIUTVyPUOuPUBvVQ>? NH3FNpczOTJ|N{WwPC=>
SU-DHL-5 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jBTlQ5yqCq MkXBS2k2OD1yLkKzJI5O MYiyNVI{PzVyOB?=
SU-DHL-8 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLNlQ5yqCq MVzHTVUxRTFwNDDuUS=> MYKyNVI{PzVyOB?=
WSU-DLCL-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojJOFjDqGh? MXjHTVUxRTFwNDDuUS=> NWLKUWM3OjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2
NCT01007292 Completed Non-Hodgkin''s Lymphoma Astellas Pharma Inc November 2009 Phase 2
NCT00498914 Terminated Lymphoma Large-Cell Diffuse|Lymphoma B-Cell Refractory Astellas Pharma Inc June 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products0

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID